JBIO vs VERA
JBIO: Jade Biosciences is a clinical-stage biotech developing next-generation monoclonal antibodies with extended half-lives to treat autoimmune diseases like IgA nephropathy and rheumatoid arthritis. VERA: Vera Therapeutics is developing atacicept, a first-in-class B-cell modulator targeting both BAFF and APRIL for autoimmune kidney diseases including IgAN, pending FDA decision in July 2026.
Side-by-side fundamentals
| Metric | JBIO | VERA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $19.85 | $36.06 | |
| Market cap as of 2026-07-23 | $1.2B | $2.6B | |
| PEG as of 2026-07-23 | n/a | -0.08 | |
| ROE as of 2026-07-23 | -51.3% | -74.9% | JBIO higher |
| ROA as of 2026-07-23 | -47.3% | -60.2% | JBIO higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.15 | JBIO lower |
| Beta as of 2026-07-23 | 1.42 | 0.89 | |
| 1-year return as of 2026-07-22 close | +136.2% | +63.1% | JBIO higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.